Journal of Cancer Research and Clinical Oncology最新文献

{"title":"Multifocal medulloblastoma in an adult: a case report and review of the literature.","authors":"Cha Luo, Fei Zhang, Xiaofeng Zhu, Ying Zeng, Zhonglian Wang, Hongting Jiang, Qing Ye, Wei Jian, Jing Zhang, Qiaofen Fu","doi":"10.1007/s00432-025-06215-9","DOIUrl":"10.1007/s00432-025-06215-9","url":null,"abstract":"<p><strong>Background: </strong>Medulloblastoma (MB) is a highly aggressive tumor originating in the cerebellum, predominantly affecting children. Adult medulloblastoma is rare, leading to a lack of a standardized treatment protocol. Although multimodal strategies from pediatric MB have improved outcomes in adult patients, challenges persist, including early diagnosis difficulties, treatment toxicity, recurrence risks, targeted therapies, and controversies over chemotherapy timing and regimen.</p><p><strong>Case description: </strong>We present a clinical case involving a 53-year-old male patient diagnosed with multifocal medulloblastoma, who presented with symptoms of dizziness. Cranial magnetic resonance imaging (MRI) revealed space-occupying lesions in the right cerebellar infratentorial region and the right temporal pole, which were initially suspected to be meningiomas. The patient subsequently underwent surgical resection of the subtentorial lesion, which was pathologically confirmed to be a medulloblastoma. Molecular classification through genetic testing classified it as the SHH subtype. Postoperatively, the patient received sequential radiotherapy and chemotherapy. After radiotherapy, the lesion in the temporal pole disappeared, and the patient recovered well. Disease-free survival of this patient was more than 2 years, during which the patient returned to the hospital for follow-up every three months. Currently, the patient is in good condition with no significant treatment sequelae or signs of recurrence.</p><p><strong>Conclusion: </strong>Adult medulloblastoma is rare, and adult multifocal medulloblastoma is even rarer. The adult patient with multifocal medulloblastoma we report underwent surgery followed by sequential radiotherapy and chemotherapy, resulting in a favorable prognosis. This may suggest that postoperative radiotherapy combined with chemotherapy could be effective in controlling adult medulloblastoma.</p>","PeriodicalId":15118,"journal":{"name":"Journal of Cancer Research and Clinical Oncology","volume":"151 5","pages":"166"},"PeriodicalIF":2.7,"publicationDate":"2025-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12078417/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144078200","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hereditary diffuse gastric and lobular breast cancer syndrome associated with germline CDH1 variants: focus on lobular breast cancer.","authors":"Giovanni Corso, Francesca Magnoni, Giorgio Bogani, Paolo Veronesi, Viviana Galimberti, Adriana Albini","doi":"10.1007/s00432-025-06222-w","DOIUrl":"10.1007/s00432-025-06222-w","url":null,"abstract":"<p><strong>Background: </strong>Hereditary lobular breast cancer (HLBC) is a distinct subset of hereditary breast cancer primarily associated with germline pathogenic variants in the CDH1 gene, which encodes E-cadherin, a crucial protein in cell adhesion. Loss of E-cadherin disrupts tissue architecture, contributing to the invasive growth pattern characteristic of lobular carcinoma. CDH1 mutations are also implicated in hereditary diffuse gastric cancer, predisposing some patients to both cancers. However, variable cancer risk is observed, as many HLBC patients with a family history of gastric cancer do not develop gastric malignancies, reflecting the complex interplay of E-cadherin's role in cell cohesion and tumorigenesis.</p><p><strong>Main body: </strong>HLBC accounts for 4-5% of lobular breast cancer cases, even in the absence of a personal or family history of gastric cancer. These tumors typically present as hormone receptor-positive (estrogen receptor-positive and progesterone receptor-positive) and are often diagnosed at advanced stages due to their diffuse growth pattern and subtle imaging characteristics. Recent evidence underscores the importance of genetic screening for CDH1 mutations in women with early-onset bilateral lobular breast cancer or a strong family history of breast cancer. Despite the strong correlation between CDH1 mutations and HLBC, the absence of diffuse gastric cancer in many patients presents diagnostic challenges. Updated guidelines emphasize targeted surveillance and risk-reduction strategies, including prophylactic mastectomy for high-risk individuals, aiming to improve clinical outcomes.</p><p><strong>Conclusion: </strong>This mini-review synthesizes recent advancements in understanding the genetics, diagnostic complexities, and clinical management of HLBC. The findings highlight the critical need for early identification and personalized approaches to optimize surveillance and therapeutic strategies for patients with this unique hereditary cancer.</p>","PeriodicalId":15118,"journal":{"name":"Journal of Cancer Research and Clinical Oncology","volume":"151 5","pages":"164"},"PeriodicalIF":2.7,"publicationDate":"2025-05-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12078353/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144025953","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Genomic profiling and pathological assessment of malignant peripheral nerve sheath tumors.","authors":"Qian Cui, Fen Zhang, Jian Liu, Jie Xu, Hongmei Wu, Fangping Xu, Qingling Zhang","doi":"10.1007/s00432-025-06209-7","DOIUrl":"10.1007/s00432-025-06209-7","url":null,"abstract":"<p><strong>Purpose: </strong>Addressing the significant clinical challenges associated with managing malignant peripheral nerve sheath tumor (MPNST), this study focuses on the difficulties encountered in achieving accurate pathological diagnosis and the exploration of effective treatment options through genomic analysis.</p><p><strong>Methods: </strong>The study included 20 patients with an initial pathological diagnosis of MPNST. Next-generation sequencing-based genomic analysis was conducted to assess the molecular features of MPNST, specifically looking for somatic mutations and actionable mutations.</p><p><strong>Results: </strong>The genomic analysis resulted in diagnostic refinement or reassignment for 20% of the cases. Somatic mutations were predominantly enriched in the RTK/RAS pathway, accounting for 64.7% of the findings. Additionally, actionable mutations were identified in 70.6% of patients who had a confirmed diagnosis of MPNST. Notably, the study revealed the presence of altered genes that were absent in Western populations, suggesting potential ethnic differences and the opportunity for alternative treatment strategies. Furthermore, patients with CDKN2A mutations exhibited significantly shorter disease-free survival compared to those without such mutations, with median survival times of 6.08 months versus 14.3 months (p = 0.0038).</p><p><strong>Conclusion: </strong>The findings emphasize the necessity of molecular testing for accurate diagnosis of MPNST, which can guide optimal therapeutic options and highlight the need for tailored treatment strategies considering the heterogeneity of pathological phenotypes and molecular features among patients.</p>","PeriodicalId":15118,"journal":{"name":"Journal of Cancer Research and Clinical Oncology","volume":"151 5","pages":"165"},"PeriodicalIF":2.7,"publicationDate":"2025-05-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12078426/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144078089","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Single-cell RNA sequencing reveals SLC31A1-mediated M2 polarization of macrophages promotes malignant progression in triple-negative breast cancer.","authors":"Xiwei Zhang, Guoqing Li, Tieyan Chen, Haohang Sun, Ji Dai, Qi Chen, Mengze Chen, Meidi Yan","doi":"10.1007/s00432-025-06191-0","DOIUrl":"10.1007/s00432-025-06191-0","url":null,"abstract":"<p><strong>Background: </strong>Among the various types of breast cancer that endanger women's lives, triple-negative breast cancer (TNBC) stands out due to its extreme heterogeneity, aggressive nature, and high likelihood of recurrence. The absence of unique targets and targeted drugs is a major factor contributing to the failure of cancer treatments and the eventual death of patients.</p><p><strong>Methods: </strong>Single-cell RNA sequencing (scRNA-seq) was applied to investigate the immune microenvironment of TNBC, facilitating the detection of key cell subpopulations and regulatory genes. The mRNA expression of SLC31A1 in macrophages was measured by qPCR. Flow cytometry was utilized to ascertain the M2 macrophage proportion and cancer cell apoptosis. Transwell and scratch assays were conducted to gauge cancer cell migration and invasion. Copper ion and H₂O₂ detection kits were employed to evaluate the copper ion content and oxidative stress levels in macrophages.</p><p><strong>Results: </strong>SLC31A1 overexpression in TNBC myeloid cells, particularly macrophage subpopulations, was identified through scRNA-seq analysis. Cluster and pseudotime analyses showed that macrophages with high SLC31A1 expression are often in advanced stages of cell growth, accompanied by notable changes in oxidative stress. Functional studies revealed that knocking down SLC31A1 in macrophages significantly reduced M2-type polarization. The conditioned medium from these macrophages markedly inhibited TNBC cell migration and invasion, while promoting apoptosis. Furthermore, SLC31A1 knockdown resulted in decreased copper ion content and H₂O₂ levels in macrophages.</p><p><strong>Conclusion: </strong>SLC31A1 enhances the malignant phenotype of TNBC cells by inducing M2 polarization in macrophages.</p>","PeriodicalId":15118,"journal":{"name":"Journal of Cancer Research and Clinical Oncology","volume":"151 5","pages":"163"},"PeriodicalIF":2.7,"publicationDate":"2025-05-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12075406/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144016277","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Overexpression of KMT9α is associated with poor outcome in cholangiocarcinoma patients.","authors":"Maximilian N Kinzler, Eric Metzger, Rebecca Schulz, Katrin Bankov, Anna Ramos-Triguero, Falko Schulze, Steffen Gretser, Nada Abedin, Armin Wiegering, Stefan Zeuzem, Dirk Walter, Henning Reis, Roland Schüle, Peter J Wild","doi":"10.1007/s00432-025-06214-w","DOIUrl":"10.1007/s00432-025-06214-w","url":null,"abstract":"<p><strong>Purpose: </strong>The newly discovered histone methyltransferase KMT9 serves as an epigenetic regulator of carcinogenesis in various cancer entities. For the first time, we investigated the presence of KMT9α in cholangiocarcinoma, the association with histologic subtypes, and its impact on survival.</p><p><strong>Methods: </strong>A tissue microarray cohort of all CCA patients who underwent surgical resection with curative intent between 08/2005 and 12/2021 at the University Hospital Frankfurt was immunohistochemically analyzed with the KMT9α antibody. For overall survival, Kaplan-Meier curves and Cox-regression analyses were performed.</p><p><strong>Results: </strong>In total, 174 patients were suitable for IHC analysis. Of the patients, 35.1% (n = 61) overexpressed KMT9α. Kaplan-Meier curves revealed a median OS of 34.75 months (95% CI = 20.23-49.27 months) for all CCA patients positive for KMT9α in comparison to 54.21 months (95% CI = 41.78-66.63 months) for patients lacking KMT9α overexpression (p = 0.004). Subtype analysis revealed strong differences in KMT9α expression. Multivariate Cox regression analysis identified KMT9α as an independent risk factor for shorter OS in CCA.</p><p><strong>Conclusion: </strong>This study demonstrates that a marked subset of CCA patients exhibit overexpression of KMT9α. These findings underscore the prognostic significance of KMT9α and reinforce its potential as a therapeutic target, consistent with its role in other cancer types.</p>","PeriodicalId":15118,"journal":{"name":"Journal of Cancer Research and Clinical Oncology","volume":"151 5","pages":"161"},"PeriodicalIF":2.7,"publicationDate":"2025-05-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12069507/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143982074","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"FOXM1 boosts glycolysis by upregulating SQLE to inhibit anoikis in breast cancer cells.","authors":"Mei Xu, Guozhi Pan, Qian Zhang, Jiangming Huang, Yehua Wu, Yashengjiang Ashan","doi":"10.1007/s00432-025-06174-1","DOIUrl":"10.1007/s00432-025-06174-1","url":null,"abstract":"<p><strong>Background: </strong>Resisting anoikis is a prerequisite for cancer to spread and invade and a major cause of cancer-related deaths. Yet, the intricate mechanisms of how cancer cells evade anoikis remain largely unknown. There is a significant need to explore how these mechanisms play out in breast cancer (BC).</p><p><strong>Methods: </strong>Bioinformatics analysis revealed the expression levels of SQLE and FOXM1 in BC tissue, along with their correlation. The enrichment pathways of SQLE were also explored. qPCR detected the expression of SQLE and FOXM1 in BC cells. CCK-8 assessed cell viability, while flow cytometry measured anoikis. Western blot was employed to examine the protein expression of key genes in glycolytic metabolism and apoptosis-related proteins. Extracellular acidification rate was quantified, and corresponding kits evaluated glucose consumption, lactate production, and adenosine triphosphate levels in cells. Dual-luciferase reporter assays and chromatin immunoprecipitation tests unveiled the binding relationship between FOXM1 and SQLE.</p><p><strong>Results: </strong>SQLE was found to be highly expressed in BC and enriched in pathways associated with anoikis and glycolysis. SQLE curbed anoikis in BC via the aerobic glycolysis pathway. There was also a direct binding between FOXM1 and SQLE and a positive correlation between their expression. Recovery experiments substantiated that FOXM1 targeted SQLE to suppress anoikis in BC cells.</p><p><strong>Conclusion: </strong>FOXM1 upregulates SQLE, which in turn mediates glycolysis to suppress anoikis in BC. The FOXM1/SQLE axis is a promising therapeutic target for BC treatment.</p>","PeriodicalId":15118,"journal":{"name":"Journal of Cancer Research and Clinical Oncology","volume":"151 5","pages":"162"},"PeriodicalIF":2.7,"publicationDate":"2025-05-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12075401/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144007033","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Random forest-based model for the recurrence prediction of borderline ovarian tumor: clinical development and validation.","authors":"Liheng Yan, Qiulin Ye, Baole Shi, Juanjuan Liu, Yuexin Hu, Ouxuan Liu, Xiao Li, Bei Lin, Yue Qi","doi":"10.1007/s00432-025-06221-x","DOIUrl":"10.1007/s00432-025-06221-x","url":null,"abstract":"<p><strong>Purpose: </strong>This study aims to develop an effective machine learning (ML)-based predictive model for the recurrence of borderline ovarian tumor (BOT), and provide the guidelines of accurate clinical diagnosis and precise treatment for patients.</p><p><strong>Method: </strong>A total of 660 patients diagnosed with BOT were included in this study. Statistical testing methods were employed to identify the most influential factors. At the same time, five machine learning-based models-random forest (RF), logistic regression (LR), gradient boosting (GB), multilayer perceptron (MLP), and support vector machine (SVM)-were utilized to construct recurrence prediction models. Model validity was assessed using five metrics: area under the curve (AUC), positive predictive value (PPV), accuracy (ACC), recall (REC), specificity (SPE), and the optimal model was selected based on these performance metrics. The calibration curve further illustrates the reliability of the model. Then, the optimal ML-based model determined the importance of features using SHAP values. Additionally, CIC and DCA, along with recurrence-free survival analysis, were employed to further assess the clinical value of the optimal model.</p><p><strong>Results: </strong>The RF model demonstrated superior predictive performance. Additionally, the SHAP analysis of the RF-based model provides the key clinical factors associated with the recurrence of BOT. Furthermore, the DCA and CIC shows the clinical application value of the RF-based model. Moreover, random forest-recurrence free survival (rf-RFS) model validate the effectiveness of the proposed method personalized treatment strategies and informed clinical decision-making of the recurrence of BOT.</p><p><strong>Conclusion: </strong>The RF-based model offers an effective tool for predicting BOT recurrence, with a user-friendly web-based calculator developed to aid clinical decision-making.</p>","PeriodicalId":15118,"journal":{"name":"Journal of Cancer Research and Clinical Oncology","volume":"151 5","pages":"160"},"PeriodicalIF":2.7,"publicationDate":"2025-05-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12066375/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144025491","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Lack of association between SLFN11 expression and treatment efficacy or survival outcomes in patients with pancreatic ductal adenocarcinoma.","authors":"Takeaki Nakamura, Kanako C Hatanaka, Yasuyuki Kawamoto, Shiho Kaneko, Koichi Ishida, Kazuaki Harada, Satoshi Yuki, Yoshito Komatsu, Yutaka Hatanaka, Naoya Sakamoto","doi":"10.1007/s00432-025-06216-8","DOIUrl":"10.1007/s00432-025-06216-8","url":null,"abstract":"<p><strong>Purpose: </strong>Pancreatic ductal adenocarcinoma (PDAC) has a poor prognosis. Despite the use of aggressive combination chemotherapy regimens, outcomes remain unsatisfactory. Schlafen family member 11 (SLFN11) has been reported to regulate the DNA damage response and influence tumor sensitivity to certain chemotherapeutic agents. This study aimed to investigate the expression of SLFN11 in PDAC and its potential as a biomarker for predicting treatment efficacy and survival outcomes.</p><p><strong>Methods: </strong>This retrospective observational cohort study included 158 patients with unresectable or borderline resectable PDAC who received palliative chemotherapy. Patients were classified into three groups: metastatic, locally advanced, and borderline resectable PDAC. Immunohistochemical staining for SLFN11 was performed on biopsy specimens, and expression levels were quantified using the histo-score (H-score). Associations between SLFN11 expression and clinical outcomes, including progression-free survival and overall survival, were analyzed using Kaplan-Meier methods and Cox regression models.</p><p><strong>Results: </strong>SLFN11 expression was observed in 54.4% of PDAC tissues. The median H-score for SLFN11 expression was higher in metastatic cases than in locally advanced and borderline resectable cases. However, no significant association was found between SLFN11 expression and the efficacy of chemotherapy or clinical outcomes.</p><p><strong>Conclusion: </strong>Despite the hypothesized role of SLFN11 as a predictive biomarker for chemotherapy efficacy, no significant association was found between SLFN11 expression and clinical outcomes in PDAC. Further studies with larger cohorts and more detailed staging are needed to clarify the potential utility of SLFN11 as a therapeutic biomarker in PDAC.</p>","PeriodicalId":15118,"journal":{"name":"Journal of Cancer Research and Clinical Oncology","volume":"151 5","pages":"159"},"PeriodicalIF":2.7,"publicationDate":"2025-05-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12064574/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143965605","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Thoracoscopy-guided thoracic paravertebral block using dexmedetomidine in combination with ropivacaine for postoperative analgesia after thoracoscopic radical resection of lung cancer: a randomized controlled trial.","authors":"Ke-Wei Wu, Shu-Yu Deng, Xu-Feng Zhang, Da-Wei Zheng, Li-Hong Hu","doi":"10.1007/s00432-025-06218-6","DOIUrl":"10.1007/s00432-025-06218-6","url":null,"abstract":"<p><strong>Purpose: </strong>The aim of this trial was to evaluate the analgesic effect of dexmedetomidine combined with ropivacaine for thoracoscopic-guided thoracic paravertebral block (TTPB) after thoracoscopic radical resection (TRR) of lung cancer.</p><p><strong>Methods: </strong>A total of 60 patients were enrolled from our hospital who underwent elective TRR of lung cancer and randomized into either a control group (group C) or a dexmedetomidine group (group D). Prior to incisional suturing, group C received ropivacaine alone for TTPB, while group D received dexmedetomidine combined with ropivacaine for TTPB. The primary outcome was the time to the first analgesic request (TFAR). The secondary outcomes included heart rate (HR), mean arterial pressure (MAP), Ramsay sedation score, and Numerical Rating Scale (NRS) scores (both at rest and during coughing) at the following time points: before the TTPB operation (T0), 1 h postoperatively (T1), 2 h postoperatively (T2), 6 h postoperatively (T3), 12 h postoperatively (T4), 24 h postoperatively (T5), as well as 48 h postoperatively (T6). Additional secondary outcomes included the patient-controlled intravenous analgesia (PCIA) sufentanil dosage at 48 h postoperatively, the incidence of adverse reactions, and postoperative recovery.</p><p><strong>Results: </strong>Compared to group C, group D showed a longer TFAR, lower total PCIA sufentanil dosage at 48 h postoperatively, and lower NRS scores at all time points; Group D also had lower MAP and HR, higher Ramsay sedation scores from T1 to T3 after surgery, a higher incidence of drowsiness, and better postoperative recovery.</p><p><strong>Conclusions: </strong>As an adjuvant in combination with ropivacaine, dexmedetomidine enhanced the analgesic effect of TTPB, prolonged the duration of analgesia, and reduced the time to first ambulation and hospital stay.</p><p><strong>Clinical trial registration: </strong>ChiCTR2400086347, Registered 28/06/2024.</p>","PeriodicalId":15118,"journal":{"name":"Journal of Cancer Research and Clinical Oncology","volume":"151 5","pages":"158"},"PeriodicalIF":2.7,"publicationDate":"2025-05-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12064592/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143967227","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Repurposing tranexamic acid as an anticancer drug: a systematic review and meta-analysis.","authors":"Karoline Assifuah Kristjansen, Nulvin Djebbara-Bozo, Kumanan Rune Nanthan, Marie Louise Bønnelykke-Behrndtz","doi":"10.1007/s00432-025-06185-y","DOIUrl":"10.1007/s00432-025-06185-y","url":null,"abstract":"<p><strong>Purpose: </strong>Drug repurposing may be an efficient strategy for identifying new cancer treatments. Tranexamic acid (TXA), an antifibrinolytic agent that affects the plasminogen-plasmin pathway, may have potential anticancer effects by influencing tumor cell proliferation, angiogenesis, inflammation, immune response, and tissue remodeling-all crucial processes contributing to tumor progression and metastasis.</p><p><strong>Objective: </strong>Evaluate TXA's anticancer effects across in vitro, animal, and clinical studies to assess its potential as a repurposed cancer drug.</p><p><strong>Methods: </strong>The study was designed as a PRISMA-compliant systematic review and meta-analysis. The literature search was conducted in MEDLINE, EMBASE, Web of Science, and the Cochrane Library. In vitro, animal, and clinical studies investigating the anticancer effects of TXA or epsilon-aminocaproic acid (EACA) were included. Animal and clinical studies were critically appraised, and studies with a low risk of bias were included in the meta-analysis.</p><p><strong>Results: </strong>Of 4367 identified records, 38 articles were included, collectively reporting findings from 41 in vitro studies, 34 animal studies (n = 843 animals), and seven clinical studies (n = 91 patients). The meta-analysis included nine animal studies and showed a tumor growth reduction in animals treated with TXA compared to controls with a standardized mean difference of - 1.0 (95%CI - 1.5; - 0.4) (p = 0.0002). Equivalently, the majority of in vitro studies reported reduced proliferation, viability, and invasiveness in TXA-exposed tumor cell lines. The clinical studies were considerably susceptible to bias, rendering any conclusions futile.</p><p><strong>Conclusions: </strong>TXA shows promise as a repurposed cancer drug, revealing an overall reduction in tumor growth, viability, and invasiveness in animal and in vitro studies.</p>","PeriodicalId":15118,"journal":{"name":"Journal of Cancer Research and Clinical Oncology","volume":"151 5","pages":"157"},"PeriodicalIF":2.7,"publicationDate":"2025-05-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12064463/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144018047","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}